% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Deleu:299524,
      author       = {A.-L. Deleu and Q. A. Shagera and S. Veldhuijzen van Zanten
                      and P. Flamen and O. Gheysens and H. Hautzel$^*$},
      title        = {{FAPI} {PET} in the {M}anagement of {L}ung {T}umors.},
      journal      = {Seminars in nuclear medicine},
      volume       = {55},
      number       = {2},
      issn         = {0001-2998},
      address      = {New York, NY [u.a.]},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2025-00482},
      pages        = {202-211},
      year         = {2025},
      note         = {2025 Mar;55(2):202-211},
      abstract     = {Fibroblast activation protein (FAP), selectively expressed
                      on activated fibroblasts in proliferating tissues, is
                      emerging as a promising target in oncology. In lung cancer,
                      the leading cause of cancer-related deaths worldwide,
                      [18F]FDG PET/CT has set the bar high and earned widespread
                      recognition in clinical guidelines for its essential role in
                      staging and follow-up. Yet, FAP-targeted imaging agents like
                      FAPI PET/CT have demonstrated significant potential due to
                      their high tumor specificity, rapid tracer uptake, and low
                      background activity. This review focuses on the role of FAPI
                      PET/CT in lung cancer, highlighting its applications in
                      staging, biomarker evaluation, and clinical management. FAP
                      expression correlates with cancer associated
                      fibroblast-driven tumorigenesis in lung cancer, showing
                      higher expression in nonsmall cell lung cancer (NSCLC) than
                      in small cell lung cancer (SCLC) subtypes. Studies reveal
                      that FAPI PET/CT provides comparable or superior detection
                      rates for primary tumors and metastases compared to [18F]FDG
                      PET/CT, particularly in brain, pleural, and bone lesions. It
                      also enhances accuracy in lymph node staging, influencing
                      disease management by enabling surgical resection in cases
                      misclassified by [18F]FDG PET/CT. Despite these advantages,
                      several challenges remain, such as differentiating benign
                      from malignant lesions, assessing FAPI's prognostic
                      implications or its role in treatment response monitoring.
                      Future directions include exploring FAPI-based theranostics,
                      standardizing radiopharmaceuticals, and conducting
                      well-designed, adequately powered prospective trials. FAPI
                      PET/CT represents a transformative diagnostic tool,
                      complementing or potentially surpassing [18F]FDG PET/CT in
                      precision lung cancer care.},
      subtyp        = {Review Article},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40037979},
      doi          = {10.1053/j.semnuclmed.2025.02.011},
      url          = {https://inrepo02.dkfz.de/record/299524},
}